Stay updated on Azacitidine and Pembrolizumab in MDS Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in MDS Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to include a new facility name and location, along with specific medical terms related to myelodysplastic syndrome and associated treatments, while removing several previous terms related to diseases and treatment classifications.SummaryDifference3%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check30 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version, v2.16.8, of the HHS Vulnerability Disclosure, replacing the previous version v2.16.6.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
Stay in the know with updates to Azacitidine and Pembrolizumab in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.